Portfolio (Quarterly)
Guide ↗
Royalty Pharma Sub-Manager, LLC
· CIK 0002081668| # | Ticker | Company | Sector | Shares | Value ↓ | % Port | Chg Shares | Chg % | Period Price ① | Since Period ① |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CYTK | CYTOKINETICS, INC | Healthcare | 980,392.0 | $83.5M | 34.52% | — | — | $85.19 | -14.6% |
| 2 | BCAX | ZENAS BIOPHARMA, INC. | Healthcare | 2,388,150.0 | $60.6M | 25.05% | — | — | $25.38 | -8.7% |
| 3 | KLRA | KAILERA THERAPEUTICS | Healthcare | 2,455,357.0 | $54.1M | 22.36% | NEW | — | $22.03 | -26.3% |
| 4 | — | BIOHAVEN LTD | — | 2,936,507.0 | $43.7M | 18.06% | — | — | $14.88 | — |
① Period Price is the implied market price on the last day of the reporting period, calculated as reported value ÷ shares held. It is not the fund's purchase price or cost basis — the fund may have initiated or added to the position at any point during the quarter at a different price. Since Period shows the price change from that quarter-end snapshot to today's last price — it reflects stock movement after the report date, not the fund's actual return.
Sector Allocation
Healthcare
100.0%